---
title: Tigermed EMEA – Achievements, Expertise, and Major Contributions in Clinical Research
description: Tigermed EMEA represents the European, Middle East, and Africa division of the global Tigermed Group – a full-service CRO with international coverage, supporting the development of pharmaceuticals and medical devices across all phases of clinical research. With rapid expansion throughout the EMEA region and a growing project portfolio, the company has strengthened its position as a strategic partner for sponsors aiming to accelerate therapy development and achieve efficient market access.
---

[Tigermed EMEA Articles](https://tigermedemea.com/blog)

# [Tigermed EMEA – Achievements, Expertise, and Major Contributions in Clinical Research](https://tigermedemea.com/blog/tigermed-emea-achievements-expertise-and-major-contributions-in-clinical-research)

 Written by [Tigermed EMEA](https://tigermedemea.com/blog/author/tigermed-emea) | Dec 1, 2025 8:29:21 AM

Tigermed EMEA represents the European, Middle East, and Africa division of the global Tigermed Group – a full-service CRO with international coverage, supporting the development of pharmaceuticals and medical devices across all phases of clinical research. With rapid expansion throughout the EMEA region and a growing project portfolio, the company has strengthened its position as a strategic partner for sponsors aiming to accelerate therapy development and achieve efficient market access.

 

 

 

## **1. Tigermed EMEA’s Footprint in the EMEA Region**

 

According to public company data, Tigermed EMEA has a strong and well-structured presence:

 

- operations in **over 20 EMEA countries**,
- **15 local offices**,
- a team of **160+ specialists across Europe**,
- experience in **over 200 Phase I–IV clinical studies** conducted in the region.

 

At the group level, Tigermed considers EMEA a strategic pillar, with **over 100 multi-regional clinical trials (MRCT)**conducted in Europe and involvement in **more than 210 clinical projects** by 2025.

 

 

## **2. Major Achievements and Strategic Contributions in Clinical Research**

 

### **1-Over 200 Clinical Studies in EMEA (Phase I–IV)**

 

The Tigermed EMEA portfolio includes studies across various therapeutic areas: oncology, endocrinology/metabolic diseases, neurology (CNS), infectious diseases, cardiovascular, rheumatology, and ophthalmology — including complex multi-country projects.

 

### **2- Proven Expertise in Large-Scale Vaccine Studies**

 

Tigermed EMEA has demonstrated experience in managing **large-scale vaccine trials**, supported by Tigermed’s global infrastructure.

 

At the group level, Tigermed has contributed to COVID-19 vaccine programs by conducting **accelerated multi-regional studies**, directly supporting rapid approval pathways.

 

### **3- Participation in the Approval of Innovative Drugs and Medical Devices**

 

Global Tigermed reports highlight:

 

- **567 drug studies** and
- **341 medical device projects** conducted in a single year,

 

as well as direct contributions to the approval of:

 

- **three innovative medical devices**,
- **two AI-based medical software solutions**,
- and support in achieving market approval for a **new CGRP receptor antagonist for migraine**, in collaboration with a global sponsor.

 

Tigermed EMEA played a key role in the European components of these programs, contributing operational, regulatory, and pharmacovigilance expertise.

 

### **4- Leadership in Decentralized Clinical Trials and Digitalization (DCT)**

 

Tigermed is a pioneer in DCT, implementing:

 

- hybrid studies with **ePRO**,
- telemedicine,
- digital tools for remote data collection,
- home IMP delivery,
- and fully digital study management.

 

Notably, Tigermed implemented a DCT component for the **Nurtec® migraine study**, enabling digital data collection.

 

Tigermed EMEA integrates these practices across Europe, adapting them to CTR and local regulatory requirements.

 

### **5- Expanding Clinical Research Across Africa**

 

Tigermed and Tigermed EMEA collaborate with organizations such as Purpose Africa and Africare to:

 

- expand clinical site networks,
- increase patient access to trials,
- develop local research infrastructure,
- and support multi-regional studies across African regions.

 

This initiative helps sponsors include diverse patient populations and access emerging markets.

 

## **3. Types of Clinical Studies Successfully Conducted**

 

Tigermed EMEA has extensive experience in:

 

### **Drug Studies (Phase I–IV)**

 

- oncology (including cell and gene therapies),
- metabolic diseases,
- infectious diseases,
- cardiovascular diseases,
- neurological and rheumatological disorders.

 

### **Vaccine Studies**

 

- traditional vaccines (influenza, HPV, etc.),
- innovative vaccine platforms, including COVID-19.

 

### **Medical Device and IVD Studies**

 

- implantable and non-implantable devices,
- medical software and AI-based solutions,
- performance and safety studies under MDR/IVDR.

 

### **Cosmetics, Nutraceuticals, and Supplements**

 

- efficacy evaluations,
- post-marketing observational studies.

 

### **Multi-Regional Clinical Trials (MRCT)**

 

Including:

 

- feasibility,
- site selection,
- project management,
- data management & statistical analysis,
- regulatory support (CTR, MDR, IVDR),
- and integrated pharmacovigilance.

 

 

## **4. Why Sponsors Choose Tigermed EMEA**

 

Tigermed EMEA’s results translate into clear advantages for partners:

 

- **Reduced risk and accelerated approval timelines**, supported by proven experience in hundreds of studies.
- **An extensive network of clinical sites across 20+ countries**, ideal for MRCT.
- **Strong expertise in large vaccine studies, medical devices, and AI-enabled solutions**, rapidly growing segments.
- **A unique ability to combine global capabilities with local expertise** across EMEA.
- **Implementation of modern technologies (DCT, ePRO, telemedicine)** for superior operational efficiency.

 

 

 

[View full post](https://tigermedemea.com/blog/tigermed-emea-achievements-expertise-and-major-contributions-in-clinical-research)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Tigermed EMEA"
  },
  "dateModified" : "2025-12-06T22:54:11.516Z",
  "datePublished" : "2025-12-01T08:29:21Z",
  "headline" : "Tigermed EMEA – Achievements, Expertise, and Major Contributions in Clinical Research",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1200,
    "url" : "https://47781279.fs1.hubspotusercontent-eu1.net/hubfs/47781279/TOTI.png",
    "width" : 800
  },
  "mainEntityOfPage" : "https://tigermedemea.com/blog/tigermed-emea-achievements-expertise-and-major-contributions-in-clinical-research",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Tigermed EMEA Articles"
  }
}
```